Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

about

Disease modification and Neuroprotection in neurodegenerative disorders.Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.

P2860

Q42363882-D0E8C0A9-771E-4E37-AB88-012EB9048301 Q48313516-518F7009-BA35-4E54-8031-84B8571AA991

P2860

Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

Item

http://www.wikidata.org/entity/Q38691690

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Longitudinal magnetic resonanc ...... ned score for clinical trials.

@en

type

Item

label

Longitudinal magnetic resonanc ...... ned score for clinical trials.

@en

prefLabel

Longitudinal magnetic resonanc ...... ned score for clinical trials.

@en

P1476

Longitudinal magnetic resonanc ...... ned score for clinical trials.

@en

P2093

AL-108-231 Investigators

http://www.w3.org/2001/XMLSchema#string

Adam L Boxer

http://www.w3.org/2001/XMLSchema#string

Jakob Schöpe

http://www.w3.org/2001/XMLSchema#string

Movement Disorder Society-Endorsed PSP Study Group

http://www.w3.org/2001/XMLSchema#string

Stefan Wagenpfeil

http://www.w3.org/2001/XMLSchema#string

Tauros MRI Investigators

http://www.w3.org/2001/XMLSchema#string

P2860

A fast diffeomorphic image registration algorithm

Structural Brain Magnetic Resonance Imaging of Limbic and Thalamic Volumes in Pediatric Bipolar Disorder

An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

Global and regional annual brain volume loss rates in physiological aging.

Short-interval observational data to inform clinical trial design in Huntington's disease.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis

Decreased volume of left and total anterior insular lobule in schizophrenia.

Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance

P304

842-852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.26973

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28436538

http://www.w3.org/2001/XMLSchema#string

P932

5808453

http://www.w3.org/2001/XMLSchema#string

Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

about

P2860

P2860

Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932